Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 7,893 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non intervention study Clear all

Conditions: Atrial Fibrillation
Interventions: Magnetic Resonance Imaging (MRI), Laboratory Testing; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 11
States / cities: Birmingham, Alabama • San Luis Obispo, California • Santa Maria, California + 8 more

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions: We Chatt communication tool, Usual/standard care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Depression, Other Diagnoses, Comorbidities, and Complications
Interventions: No treatment; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 10 Years to 89 Years
Enrollment: 447 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nausea
Interventions: Acupressure expectancy enhancement; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hematological Malignancy, Solid Tumor Malignancy
Interventions: No Intervention; Other
Lead sponsor: Century Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 7
States / cities: Gilbert, Arizona • Los Angeles, California • Baltimore, Maryland + 4 more

Conditions: Biliary Dyskinesia
Interventions: CCK Injection and Ultrasound; Procedure
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • Newport Beach, California

Conditions: Coronary Atherosclerosis
Interventions: Hexadecasaccharide (SR123781A); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes
Interventions: Home Telehealth with Behavioral Education Component; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Durvalumab, Placebo to MK-1084; Drug · Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 8
States / cities: Atlanta, Georgia • Savannah, Georgia • Lisle, Illinois + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 74
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more

Conditions: Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions: Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 19 Years to 30 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions: No intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Suicide Prevention
Interventions: GRIT, GRI; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: West Haven, Connecticut • Providence, Rhode Island

Conditions: Psychology, Social, Adolescent Behavior
Interventions: Video games and violence; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 8 Years to 12 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Spinocerebellar Ataxia Type 3
Interventions: Specimen Collection; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Colorectal Cancer
Interventions: Auto Mailing Plus Money, Auto Mailing Plus Lottery; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years to 75 Years
Enrollment: 898 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions: Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 30 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Conditions: Open Fracture
Interventions: Vancomycin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Colon Adenoma, Colon Polyp, Colon Lesion
Interventions: Computer-Assisted Detection (CADe) Device; Device
Lead sponsor: Verily Life Sciences LLC; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 1,410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Rochester, Minnesota • Durham, North Carolina • Mentor, Ohio + 2 more

Conditions: HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami Beach, Florida • Kansas City, Missouri

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 12 more

Search by objective public record fields.

A Study to Assess the Use of The Sentinel Device During Atrial Fibrillation Ablation

A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

A Study to Improve Physician-Youth Communication and Medical Decision Making

UTSW Depression Cohort: A Longitudinal Study of Depression

Acupressure and Relaxation for Nausea Control

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Ultrasound for Diagnosis of Biliary Dyskinesia

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction

Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Diabetes Mellitus

Retreat-Based Program for Violence-Exposed Women Veterans

Exposure to Gun Violence in Video Games Increases Interest in Real Guns

Identification of Biomarkers in Spinocerebellar Ataxia 3

Financial Incentives to Increase Colorectal Cancer Screening in Priority Populations

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Placement of Antibiotic Powder in Wounds During the Emergency Room

Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study)

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin